Highest-materiality recent filing
Zoetis director Louise Parent retires; annual meeting approves all management proposals
Director Louise M. Parent retired effective May 20, 2026 under company retirement policy.
Zoetis declares Q3 2026 dividend of $0.53 per share
Quarterly dividend set at $0.53 per share for Q3 2026.
Zoetis Q1 revenue flat organic; cuts FY 2026 guidance on softer demand and competition
Revenue $2.3B, +3% reported but flat organic; net income $601M ($1.42 EPS), flat YoY.
Zoetis Q4 2025 revenue $2.4B (+3%), EPS $1.37; FY26 guidance $9.825-10.025B
Q4 2025 revenue $2.4B (+3% reported, +4% organic); net income $603M (EPS $1.37, +6%).
Zoetis declares Q2 2026 dividend of $0.53 per share
Dividend of $0.53 per share declared for second quarter of 2026.
Zoetis issues $2B of 0.25% convertible notes due 2029; proceeds for stock buyback and capped calls
Aggregate principal $2.0B (including $250M option exercised); 0.25% semi-annual interest; matures June 15, 2029.
Zoetis declares $0.53 per share quarterly dividend for Q1 2026
Zoetis declared a quarterly dividend of $0.53 per share for Q1 2026.
Zoetis posts Innovation Webcast presentation; no material financial details provided
Innovation Webcast scheduled for Dec 2, 2025 at 8:30 a.m. ET.
Zoetis Q3 adjusted EPS $1.70 (+8%); revenue $2.4B (+4% organic); FY guidance narrowed
Q3 revenue $2.4B (+1% reported; +4% organic operational); net income $721M, $1.63 diluted EPS (+9% YoY).
Zoetis appoints Stephanie Tilenius to Board, effective Dec 1, 2025
Stephanie Tilenius appointed to Zoetis Board, effective December 1, 2025.
Zoetis declares $0.50 per share Q4 dividend, payable Dec 2, 2025
Dividend of $0.50 per share declared for Q4 2025.
Zoetis enters $1.25B revolver, replaces 2022 facility; can increase to $1.75B
New five-year $1.25B senior unsecured revolving credit facility, maturing August 2030.
Zoetis issues $1.85B in senior notes: $850M at 4.150% due 2028, $1B at 5.000% due 2035
Issued $850M 4.150% Senior Notes due 2028 and $1B 5.000% Senior Notes due 2035.
Zoetis Q2 revenue $2.5B (+4% reported, +8% organic); raises FY2025 guidance
Reported net income $718M ($1.61 diluted EPS), up 15% YoY; adjusted EPS $1.76, up 13%.
Zoetis appoints Mark Stetter to board; Robert Scully retires
Robert Scully retired from Zoetis board effective May 21, 2025, under director retirement policy.
Zoetis declares $0.50/share quarterly dividend for Q3 2025
Dividend of $0.500 per share declared for third quarter 2025.
Zoetis Q1 2025 revenue $2.2B (+9% organic), adj EPS $1.48; affirms 6-8% organic growth for FY
Revenue $2.2B (+1% reported, +9% organic operational); net income $631M, diluted EPS $1.41.
Zoetis Q4 revenue $2.3B (+5%), adj. EPS $1.40; FY2025 guidance organic growth 6-8%
Q4 2024 revenue $2.3B (+5% reported, +9% organic operational); reported EPS $1.29, adjusted EPS $1.40.
Zoetis declares $0.500 per share quarterly dividend for Q2 2025
Dividend of $0.500 per share declared for second quarter 2025.
Zoetis presents at J.P. Morgan Healthcare Conference on Jan 14, 2025; focus on growth strategy
Members of Zoetis management to present at 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025.
Zoetis declares $0.500 quarterly dividend payable March 4, 2025
Dividend of $0.500 per share for Q1 2025 declared on Dec 12, 2024.
Zoetis announces leadership reshuffle: CTO Mamilli leaving, new CCO and US President appointed
Wafaa Mamilli (EVP, Chief Digital & Technology Officer) to leave early 2025 for external opportunity; Keith Sarbaugh promoted to EVP and Chief Digital & Technology Officer, effective immediately.
Zoetis Q3 revenue $2.4B (+11%); adjusted EPS $1.58; FY guidance raised
Revenue $2.4B, +11% reported (+14% operational); GAAP EPS $1.50 (+16% YoY).
Zoetis declares Q4 2024 dividend of $0.432 per share
Dividend of $0.432/share declared for Q4 2024, payable Dec 3, 2024.
Zoetis Q2 2024: revenue $2.4B (+11% op), adj EPS $1.56 (+20% op), raises FY guidance
Revenue $2.4B, +8% reported / +11% operational; U.S. +12%, International +10% op.
Zoetis announces $6B share repurchase program, replacing $3.5B program expected to finish in 2024
Board approved up to $6 billion in share repurchases with no expiration date.
Zoetis announces separation from EVP, General Counsel Heidi Chen; consulting fee $350K
Heidi Chen steps down as EVP, General Counsel effective April 16, 2024; remains non-officer employee through July 16, 2024.
Zoetis shareholders approve officer exculpation; director Linda Rhodes retires
Director Linda Rhodes retired from the board effective May 21, 2024, per the retirement policy.
Zoetis declares Q3 2024 dividend of $0.432 per share, payable September 4
Quarterly dividend of $0.432 per share declared for Q3 2024, unchanged from previous quarter.
Zoetis Q1 revenue $2.2B (+10% reported, +12% operational); adj EPS $1.38, +5% reported
Reported net income $599M ($1.31 diluted EPS) +9%; adjusted net income $634M ($1.38 adj EPS) +5% reported, +17% operational.
Zoetis EVP, General Counsel Heidi C. Chen to step down; interim named
Heidi C. Chen to cease as EVP, General Counsel and Corporate Secretary effective April 16, 2024.
Zoetis appoints Gavin Hattersley to Board, increases size to 13
Gavin D.K. Hattersley appointed to Zoetis Board effective April 1, 2024.
Zoetis Q4 2023 revenue $2.2B (+8%), adj. EPS $1.24; FY2024 guidance $9.075-9.225B
Q4 revenue $2.2B (+8% reported & operational); net income $525M ($1.14 diluted EPS), up 14% and 15% respectively.
Zoetis declares Q2 2024 dividend of $0.432 per share
Quarterly dividend of $0.432 per share declared for Q2 2024.
Zoetis declares Q1 2024 dividend of $0.432 per share
Dividend of $0.432 per share declared for Q1 2024.
Zoetis Q3 revenue $2.2B (+8% operational), EPS $1.29; narrows FY guidance
Revenue $2.2B, up 7% reported / 8% operational; net income $596M ($1.29 EPS), +13%/+14%.
Zoetis declares Q4 2023 dividend of $0.375 per share
Dividend of $0.375 per share declared by Board on October 12, 2023.
Revenue $2.2B, +6% reported, +9% operational; net income $671M ($1.45 EPS) +27%/29%.
Zoetis Investor Day targets mid-to-high single-digit revenue growth, $1B+ peak OA pain franchise
Annual revenue growth target of mid-to-high single digits over next 3-5 years.
Zoetis shareholders approve special meeting right amendment at 2023 annual meeting
Special Meeting Amendment to Restated Certificate approved with 364M votes for, 2M against, 35.9M abstentions.
Zoetis declares $0.375 quarterly dividend for Q3 2023
Dividend of $0.375 per share declared for third quarter 2023.
Zoetis Q1 revenue $2.0B (+1% reported, +4% operational); adj. EPS $1.31, down 1% operationally
Reported net income $552M ($1.19 diluted EPS), down 7% and 6% YoY respectively.
Zoetis Q4 revenue $2.0B (+9% operational); adj. EPS $1.15; FY23 guide $8.575-8.725B
Q4 revenue $2.0B (+4% reported, +9% operational); net income $461M ($0.99 EPS); adj. net income $539M ($1.15 adj. EPS).
Zoetis declares $0.375/share quarterly dividend for Q2 2023
Dividend of $0.375 per share declared for second quarter 2023.
Zoetis fires EVP Glenn David for undisclosed relationship; interim head named
Glenn David, EVP and Group President of U.S. Operations and Global Diagnostics, terminated Feb 5 for violating company policy (consensual personal relationship, failure to disclose).
Zoetis enters into $1.0B revolving credit facility, replaces prior agreement
New five-year $1.0B senior unsecured revolving credit facility with a syndicate of banks; JPMorgan as administrative agent.
Zoetis declares $0.375/share Q1 2023 dividend; payable March 1
Dividend of $0.375 per common share for Q1 2023, payable March 1, 2023, record date January 20, 2023.
Zoetis issues $1.35B in senior notes: $600M at 5.400% due 2025 and $750M at 5.600% due 2032
Issued $600M of 5.400% Senior Notes due 2025 and $750M of 5.600% Senior Notes due 2032.
Zoetis Q3 2022 revenue $2.0B (+1%), net income $529M; cuts FY 2022 guidance
Revenue $2.0B, +1% reported (+5% operational); net income $529M ($1.13 diluted EPS), down 4% and 3%.
Glenn David becomes EVP and Group President, U.S. Operations, Global Diagnostics and BioDevices effective Nov 1, 2022.
Effective May 20, 2026, Ms. Louise M. Parent retired from the Board of Directors of Zoetis Inc. (the “Company”), prior to the Company’s 2026 Annual Meeting of Shareholders (the “Annual Meeting”) in accordance with the Company’s director retirement policy.
Effective May 21, 2025, Dr. Mark Stetter was elected to the Board of Directors of the company at the Annual Meeting.
Effective May 21, 2025, Mr. Robert Scully retired from the Board of Directors of Zoetis Inc.
On November 11, 2024, Wafaa Mamilli, currently Executive Vice President, Chief Digital & Technology Officer and Group President for China, Brazil and Precision Animal Health, informed Zoetis Inc. (the “Company”) of her decision to leave the Company in early 2025 to pursue an external opportunity.
As a result of Ms. Mamilli’s planned departure, Keith Sarbaugh has been promoted to the role of Executive Vice President and Chief Digital & Technology Officer effective immediately.
On May 20, 2024, in connection with Heidi C. Chen’s previously announced separation, Zoetis Inc. (the “Company”) entered into a Letter Agreement
Effective May 21, 2024, Dr. Linda Rhodes retired from the Board of Directors of Zoetis Inc. (the “Company”), prior to the Company’s 2024 Annual Meeting of Shareholders (the “Annual Meeting”) in accordance with the Company’s director retirement policy.
Effective April 16, 2024, Heidi C. Chen will cease her role as Executive Vice President, General Counsel and Corporate Secretary, and Business Lead of Human Health Diagnostics of Zoetis Inc. (the “Company”).
Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Global Operations, will serve as interim General Counsel and Corporate Secretary while the Company conducts a search for Ms. Chen’s permanent replacement.
On April 1, 2024, the Board of Directors (the "Board") of Zoetis Inc. (the “Company”) appointed Gavin D.K. Hattersley to the Board,
On February 5, 2023, Zoetis terminated Glenn David, Executive Vice President and Group President, U.S. Operations, Global Diagnostics and BioDevices at Zoetis Inc. (the “Company”), for violating company policy by engaging in a consensual personal relationship and failing to disclose it to the Company.
William (“Chip”) Dorsey, Vice President, Finance will serve as interim head of U.S. Operations and Global Diagnostics while the Company conducts a search for Mr. David’s permanent replacement.
Max materiality 0.85 · Median 0.50 · Most common event dividend